Pharmaceutical major Zydus Cadila has applied for Emergency Use Authorisation (EUA) seeking DCGI’s approval for the launch of their ZyCoV-D vaccine for 12 years and above.
Sources said that the company has completed third phase clinical trials for the vaccine.
ZyCoV-D is the world’s first DNA vaccine against coronavirus and the fourth to become available in the country. The vaccine is a three-dose vaccine, with jabs to be administered at day 0, day 28, and day 56.
Notably this is the second indigenously developed vaccine after Bharat Biotech’s Covaxin.. The company has said it is also working on a two-dose regimen of this vaccine.
DCGI asks states to keep vigil on sale of falsified versions of 2 drugs following WHO alerts
Karnataka govt sets up panel to probe into alleged COVID irregularities during BJP regime
Kerala govt decides to provide free Onam kits to poor families, residents of welfare institutions
K’taka govt withdraws cases against CM Siddaramaiah & Deputy CM Shivakumar for COVID-19 rule violation
The stability data of the vaccine candidate showed that ZyCoV-D can be stored at 2 to 8 degrees Celsius for long-term use and 25 degrees Celsius for the short term.